Neoplasms, nausea, vomiting
Conditions
Interventions
Experimental group: 34 patients undergoing chemotherapy received face-to-face counseling, followed by four phone calls (6 hours after chemotherapy, 24 hours, 3 days and 5 days) in a nursing consultati
Other
Sponsors
Instituto do Câncer do Ceará
Hospital Haroldo Juaçaba
Eligibility
Age
No minimum to 100 Years
Inclusion criteria
Inclusion criteria: Patients aged 18 years and over, patients receiving moderate chemotherapy and high emetogenic potential (intravenous busulfan, carboplatin, combination of doxorubicin or epirubicin with cyclophosphamide, carmustine, cisplatin, intravenous cyclophosphamide, cytarabine (dose> 200mg / m²);Dacarbazine; Dactinomycin; Doxorubicin; Epirubicin (dose> 90 mg / m², ifosfamide (dose> 2 g / m²), mechlorethamine, melphalan, methotrexate (dose> 250 mg / m²), streptozocin, oxaliplatin)
Exclusion criteria
Exclusion criteria: Cancer of the gastrointestinal tract; Drug therapy with tramadol; Patients who drink alcohol during the treatment period; Patients undergoing daily chemotherapy regimens, these being given individually or in combination therapy, intravenous or oral routes (busulfan, cyclophosphamide, etoposide, procarbazine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in nausea score by 20% after 5 days of follow-up through telephone nursing consultation, assessed by the scale of the Multinational Association of Supportive Care | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of rehospitalization due to excessive nausea and vomiting 20%, identified through telephone consultation | — |
Countries
Brazil
Contacts
Public ContactAndressa;Geórgia França;Melo
Instituto do Câncer do Ceará;Universidade Federal do Ceará
Outcome results
None listed